Morgan Stanley analyst Terence Flynn maintains $CRISPR Therapeutics (CRSP.US)$ with a sell rating, and maintains the target price at $45.
According to TipRanks data, the analyst has a success rate of 54.8% and a total average return of 8.7% over the past year.
Furthermore, according to the comprehensive report, the opinions of $CRISPR Therapeutics (CRSP.US)$'s main analysts recently are as follows:
The company's Q3 update showcased the CTX112 ASH abstract in B-cell malignancies, which presented promising initial efficacy according to the analyst's research note.
The journey for patients undergoing treatment with Casgevy is not brief, yet there are emerging indicators of growing demand. Notably, beyond the first patient infusion, over forty patients have progressed through at least one cell collection phase. Caution is exercised while gauging the time it will take for patient treatment to translate into revenue and subsequently profitability. In terms of upcoming developments, recent data from a lymphoma study showcased a 6-month complete response rate of 44%. Anticipation is high for the comprehensive data reveal to gain a clearer picture of the treatment's potential in the realms of both oncology and autoimmune diseases.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
摩根士丹利分析师Terence Flynn维持$CRISPR Therapeutics (CRSP.US)$卖出评级，维持目标价45美元。
根据TipRanks数据显示，该分析师近一年总胜率为54.8%，总平均回报率为8.7%。
此外，综合报道，$CRISPR Therapeutics (CRSP.US)$近期主要分析师观点如下：
该公司的第三季度更新展示了关于b细胞恶性肿瘤的 CTX112 ASH 摘要，根据分析师的研究报告，该摘要显示出令人鼓舞的初步疗效。
接受Casgevy治疗的患者的旅程并不短暂，但有一些新迹象表明需求不断增长。值得注意的是，除了首次患者输液外，已有40多名患者经历了至少一个细胞收集阶段。在衡量患者治疗转化为收入和随后的盈利能力所需的时间时要谨慎行事。就即将取得的进展而言，一项淋巴瘤研究的最新数据显示，6个月的完全缓解率为44％。人们对所揭示的全面数据寄予厚望，这些数据将更清楚地了解该疗法在肿瘤学和自身免疫性疾病领域的潜力。
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
